Loading Events
  • This event has passed.

The Alzheimer’s Treatment Controversy: Implications of Accelerated Drug Approvals

July 20th, 2021 @ 12:00 pm - 12:30 pm

Alzheimers drug

The Alzheimer’s Treatment Controversy: Implications of Accelerated Drug Approvals

Live Online Q&A with Aaron Kesselheim, Professor of Medicine, Harvard Medical School, and Director, Program On Regulation, Therapeutics, And Law (PORTAL), Brigham and Women’s Hospital

Presented jointly with Reuters

Post your questions for the Q&A on: @ForumHSPH or @pritheworld #FDA #Alzheimers

Or email them to theforum@hsph.harvard.edu

This Q&A will stream on Facebook , YouTube, and on ForumHSPH.org

The recent controversy surrounding the FDA approval of a new Alzheimer’s treatment has prompted questions about the standards that should be used to evaluate investigational drugs. The drug, aducanumab (brand name, Aduhelm), received FDA approval despite an independent advisory committee nearly unanimously rejecting the drug; the group described a lack of convincing evidence that the drug slowed progression of cognitive dysfunction in patients with Alzheimer’s and presented important safety concerns. Dr. Aaron Kesselheim, who served on the panel that advised against the drug, will discuss the situation from his perspective during this live online Q&A with Reuters’ Julie Steenhuysen. Included will be a discussion of possible reforms to the FDA’s accelerated approval pathway, a program intended to facilitate faster drug approvals based on indirect measures of benefits.


Date: July 20th, 2021
Time: 12:00 pm - 12:30 pm
Calendars: Public Events, School-wide Events, University-wide Events
Event types: Lectures / Seminars / Forums